The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jan. 12, 2016
Filed:
Jul. 09, 2013
Applicant:
Sequoia Pharmaceuticals, Inc., Gaithersburg, MD (US);
Inventors:
Michael Eissenstat, Frederick, MD (US);
Dehui Duan, Gaithersburg, MD (US);
Assignee:
Sequoia Pharmaceuticals, Inc., Potomac, MD (US);
Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 31/343 (2006.01); C07D 405/14 (2006.01); A61K 31/33 (2006.01); A61K 31/4155 (2006.01); A61K 31/4178 (2006.01); A61K 31/4184 (2006.01); A61K 31/4196 (2006.01); A61K 31/427 (2006.01); A61K 31/4427 (2006.01); A61K 31/4709 (2006.01); A61K 45/06 (2006.01); A61K 31/437 (2006.01); A61K 31/4433 (2006.01); A61K 31/4545 (2006.01); C07D 307/79 (2006.01); C07D 405/12 (2006.01); C07D 417/12 (2006.01); C07D 471/04 (2006.01); C07D 491/048 (2006.01);
U.S. Cl.
CPC ...
C07D 405/14 (2013.01); A61K 31/33 (2013.01); A61K 31/343 (2013.01); A61K 31/4155 (2013.01); A61K 31/4178 (2013.01); A61K 31/4184 (2013.01); A61K 31/4196 (2013.01); A61K 31/427 (2013.01); A61K 31/437 (2013.01); A61K 31/4427 (2013.01); A61K 31/4433 (2013.01); A61K 31/4545 (2013.01); A61K 31/4709 (2013.01); A61K 45/06 (2013.01); C07D 307/79 (2013.01); C07D 405/12 (2013.01); C07D 417/12 (2013.01); C07D 471/04 (2013.01); C07D 491/048 (2013.01);
Abstract
Methods of inhibiting cytochrome P450 enzymes are provided that can be used for improving the treatment of diseases by preventing degradation of drugs or other molecules by cytochrome P450. Pharmaceutical compositions are provided that can act as boosters to improve the pharmacokinetics, enhance the bioavailability, and enhance the therapeutic effect of drugs that undergo in vivo degradation by cytochrome P450 enzymes.